Product nameAnti-IL-33 antibody [Nessy-1]
See all IL-33 primary antibodies
DescriptionMouse monoclonal [Nessy-1] to IL-33
Specificityab54384 recognizes pro IL33 (precursor) and mature IL33.
Tested applicationsSuitable for: WB, IP, ELISA, IHC-Pmore details
Species reactivityReacts with: Mouse, Human
Recombinant fragment corresponding to Human IL-33 aa 112-270.
This product was changed from ascites to tissue culture supernatant on 12th September 2018. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferConstituent: PBS
Concentration information loading...
PurityProtein G purified
Purification notesPurified from TCS
Our Abpromise guarantee covers the use of ab54385 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Predicted molecular weight: 31 kDa.|
|ELISA||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
FunctionCytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:16286016). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an "alarmin", that amplifies immune responses during tissue injury (PubMed:17853410, PubMed:18836528).
In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets (PubMed:21734074). This form is rapidely lost upon angiogenic or proinflammatory activation (PubMed:18787100).
Tissue specificityExpressed at high level in high endothelial venules found in tonsils, Peyer patches and mesenteric lymph nodes. Almost undetectable in placenta.
Sequence similaritiesBelongs to the IL-1 family. Highly divergent.
DomainThe homeodomain-like HTH domain mediates nuclear localization and heterochromatin association.
modificationsThe full length protein can be released from cells and is able to signal via the IL1RL1/ST2 receptor. However, proteolytic processing by CSTG/cathepsin G and ELANE/neutrophil elastase produces C-terminal peptides that are more active than the unprocessed full length protein. May also be proteolytically processed by calpains (PubMed:19596270). Proteolytic cleavage mediated by apoptotic caspases including CASP3 and CASP7 results in IL33 inactivation (PubMed:19559631). In vitro proteolytic cleavage by CASP1 was reported (PubMed:16286016) but could not be confirmed in vivo (PubMed:19465481) suggesting that IL33 is probably not a direct substrate for that caspase.
Cellular localizationNucleus. Chromosome. Cytoplasmic vesicle, secretory vesicle. Secreted. Associates with heterochromatin and mitotic chromosomes (PubMed:17185418).
- Information by UniProt
- C9orf26 antibody
- CHROMOSOME 9 OPEN READING FRAME 26 antibody
- DKFZp586H0523 antibody
All lanes : Anti-IL-33 antibody [Nessy-1] (ab54385) at 1/1000 dilution
Lane 1 : Liver Lysate
Lane 2 : Liver Cell Lysate
Lysates/proteins at 25 µg per lane.
All lanes : Goat anti-mouse HRP conjugated polyclonal antibody at 1/1000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 31 kDa
Exposure time: 2 minutes
This product has been referenced in:
- Luo Q et al. Interleukin-33 Protects Ischemic Brain Injury by Regulating Specific Microglial Activities. Neuroscience 385:75-89 (2018). Read more (PubMed: 29906552) »
- Yang Y et al. Hepatoprotective Effect of San-Cao Granule on Con A-Induced Liver Injury in Mice and Mechanisms of Action Exploration. Front Pharmacol 9:624 (2018). Read more (PubMed: 29946260) »